Trial Profile

Flunarizine for Treatment Resistant Absence Epilepsy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flunarizine (Primary)
Indications Absence epilepsy
Focus Proof of concept; Therapeutic Use

Most Recent Events

29 Nov 2023 Status changed from recruiting to discontinued.
10 Nov 2021 According to a Xenon Pharmaceuticals media release, to date, a total of eight subjects have been enrolled in this trial.
11 Aug 2021 According to a Xenon Pharmaceuticals media release, the study has expanded to include an additional site, which is currently screening patients. Additional results from a larger data set are anticipated by the end of this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com